At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m (1) TP).

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

MIT researchers have developed an experimental mRNA-based therapy that restored key immune functions lost with age in mice.

Stanford scientists have uncovered how mRNA COVID-19 vaccines can very rarely trigger heart inflammation in young men — and how that risk might be reduced. They found that the vaccines can spark a two ...

A research team led by Václav Vopálenský and Martin Pospíšek from the Faculty of Science, Charles University, has discovered ...

An analysis of ongoing trials suggests that mRNA cancer vaccines have the potential to deliver health benefits worth $75 ...

A trio of mRNA molecules could help guard against the harmful effects of aging on immune cells, a study in mice finds. A new ...

Every winter, Austin gets walloped by cedar fever: runny noses, scratchy throats, watering eyes, and canceled plans as ...